Notorium (Bromazepam)

Bromazepam, the active ingredient in Notorium, is a benzodiazepine presented as an oral tablet for oral use. It is indicated for the management of anxiety disorders and provides short‑term relief of anxiety symptoms in adult patients.

GNH USA supplies Notorium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia and the Americas. Customers benefit from comprehensive regulatory support and timely delivery.

Bromazepam is a benzodiazepine that acts on the central nervous system to alleviate anxiety‑related conditions.

- Generalized anxiety disorder: reduces excessive worry and tension. - Panic disorder: diminishes frequency and intensity of panic attacks. - Short‑term situational anxiety: provides rapid relief of acute anxiety symptoms.

Bromazepam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Fatigue: persistent lack of energy. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: difficulty with fine motor tasks.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe hypotension: marked drop in blood pressure. - Paradoxical aggression or agitation: unexpected increase in hostility or anxiety. - Dependence and withdrawal seizures: risk of physical dependence with abrupt discontinuation.

When prescribing bromazepam, clinicians should consider several safety measures to minimise risk.

- Assess renal and hepatic function: evaluate before initiating therapy. - Monitor for dependence: watch for signs of tolerance or misuse. - Avoid abrupt discontinuation: taper dose gradually under medical supervision. - Use caution in elderly patients: increased sensitivity to sedative effects. - Contraindicate with acute narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Store at ambient temperature: keep in original container, protect from moisture and light.

Bromazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol): may cause profound sedation or respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase bromazepam plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Antidepressants that affect serotonin (e.g., SSRIs): may enhance central nervous system effects. - Antihistamines (e.g., diphenhydramine): can increase sedation.